

More than animals.
More than technology.

Contact details:

Paweł Wielgus
Member of the Board
pawel.wielgus@bioceltix.com
+48 600 880 790

Bioceltix

Bierutowska 57-59 Str., building III
51-317 Wrocław, Poland
ir@bioceltix.com



We are a biotechnology company developing biological medicines based on stem cells

Used in the treatment of inflammatory and autoimmune diseases in pets

Currently we focus on:

- Osteoarthritis in dogs
- Atopic dermatitis in dogs
- Osteoarthritis in horses



| | |
|--|--|
| | Mesenchymal stem cells as an Active Pharmaceutical Ingredient |
| | Immunomodulatory properties |
| | Large scale GMP production facility with clear and simple approach for further upscaling |
| | Very good Target Animal Safety results for all products |
| | Waste-derived adipose tissue as a source (donor) material |
| | Full marketing authorisation pathway (EMA) |
| | Causative treatment potential |

| Product | BCX-CM-J | BCX-EM | BCX-CM-AD |
|----------------------------|----------|--------|--------------------------------|
| Species | | | |
| Condition | OA | OA | AD |
| Route of administration | i.a. | i.a. | i.v. |
| Target Animal Safety | ✓ | ✓ | ✓ |
| Pivotal study | ✓ | ✓ | ✓ |
| Application to EMA | ✓ | ✓ | Second indication for BCX-CM-J |
| List of questions from EMA | ✓ | ✓ | |